US-based BioAge Labs, Inc. has announced a strategic research partnership with Swiss pharmaceutical giant Novartis (NYSE: NVS). This multi-year collaboration aims to identify and validate novel therapeutic drug targets by delving into the biological mechanisms that underpin aging-related diseases and the beneficial effects of physical exercise. The partnership is designed to leverage cutting-edge research to develop new treatments for conditions associated with aging.
Financial Terms and Commitment to Research Milestones
Under the agreement, Novartis will make an initial payment and provide research funding totaling USD 20 million. Additionally, Novartis is committed to a long-term investment of up to USD 530 million for research, development, and commercial milestone payments. This significant financial commitment underscores the potential impact of the partnership on the discovery and development of new therapeutics.
Combining Expertise in Human Longevity and Exercise Biology
The collaboration will draw on BioAge’s extensive proprietary human longevity datasets and Novartis’ expertise in exercise biology. By applying advanced analytics and machine learning techniques to this comprehensive dataset, the partnership aims to identify the determinants of a healthy lifespan, effectively fueling therapeutic discovery and development.
Mutual Benefits and Rights to Novel Targets
Both BioAge Labs and Novartis will have the right to advance novel targets discovered through the collaboration. Each company will be eligible to receive reciprocal success milestones and tiered royalties, ensuring a shared interest in the success of the identified therapeutic targets and their commercialization.-Fineline Info & Tech
